tesaglitazar has been researched along with Dyslipidemias in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cox, SL | 1 |
| Birketvedt, GS; Edwards, S; Fagerberg, B; Gause-Nilsson, I; Halldórsdóttir, S; Halmos, T; Lopatynski, J; Ohman, KP; Schuster, H; Stender, S; Tonstad, S | 1 |
| Lindberg, MB; Ohman, KP; Ose, L; Retterstøl, K; Svensson, M; Tonstad, S | 1 |
1 review(s) available for tesaglitazar and Dyslipidemias
| Article | Year |
|---|---|
Tesaglitazar: a promising approach in type 2 diabetes.
Topics: Alkanesulfonates; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Insulin Resistance; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
2 trial(s) available for tesaglitazar and Dyslipidemias
| Article | Year |
|---|---|
Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
Topics: Adult; Aged; Alkanesulfonates; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins B; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Humans; Insulin Resistance; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma | 2008 |
The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Topics: Adult; Alkanesulfonates; Anticholesteremic Agents; Atorvastatin; Chemotherapy, Adjuvant; Cross-Over Studies; Drug Combinations; Drug Synergism; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Phenylpropionates; Pioglitazone; Placebos; PPAR alpha; PPAR gamma; Pyrroles; Thiazolidinediones | 2007 |